Table 1. Baseline characteristics of the study cohort.
| Parameter | |
| Gender (n) | |
| -Male | 20 (61%) |
| -Female | 13 (39%) |
| Age (years) | |
| -Mean ± SD | 44±14 |
| HBeAg status (n) | |
| -HBeAg positive | 12 (36%) |
| -HBeAg negative | 15 (45%) |
| Inactive HBsAg carrier (n) | 6 (18%) |
| Ethnicity | |
| -Caucasian | 27 (82%) |
| -Asian | 4 (12%) |
| -Afro-American | 2 (6%) |
| Genotype (n) | |
| -Genotype A | 18 (54%) |
| -Genotype B | 1 (3%) |
| -Genotype C | 3 (9%) |
| -Genotype D | 10 (30%) |
| -Genotype E | 1 (3%) |
| Hepatic Fibrosis (Ishak staging) (n) | |
| F0 | 3 (9%) |
| F1 | 6 (18%) |
| F2 | 6 (18%) |
| F3 | 2 (6%) |
| F4 | 1 (3%) |
| F5 | 2 (6%) |
| F6 | 0 |
| Not available | 13 (39%) |
| Organ transplantation (n) | |
| -Liver transplantation | 5 (15%) |
| -Renal transplantation | 4 (12%) |
| Duration of NUC therapy (months) | |
| -Mean ± SD | 34±21 |
| -Median (range) | 28 (11–111) |
| Treatment regimen (n) | |
| -Lamivudine (LAM) monotherapy | 8 |
| -Adefovir (ADV) monotherapy | 6 |
| -Telbivudine (LDT) monotherapy | 1 |
| -Entecavir (ETV) monotherapy | 2 |
| -Tenofovir (TDF) monotherapy | 2 |
| -Lamivudine+Adefovir | 6 |
| -Lamivudine/Entricitabine+Tenofovir | 6 |
| -Tenofovir+Entecavir | 5 |